VB10.16 Immunotherapy (DNA vaccine)
Phase 1/2Completed 2 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Grade Cervical Intraepithelial Neoplasia
Conditions
High Grade Cervical Intraepithelial Neoplasia
Trial Timeline
Aug 1, 2015 → Jan 31, 2019
NCT ID
NCT02529930About VB10.16 Immunotherapy (DNA vaccine)
VB10.16 Immunotherapy (DNA vaccine) is a phase 1/2 stage product being developed by Nykode Therapeutics for High Grade Cervical Intraepithelial Neoplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT02529930. Target conditions include High Grade Cervical Intraepithelial Neoplasia.
What happened to similar drugs?
3 of 20 similar drugs in High Grade Cervical Intraepithelial Neoplasia were approved
Approved (3) Terminated (6) Active (12)
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
9
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02529930 | Phase 1/2 | Completed |
Competing Products
20 competing products in High Grade Cervical Intraepithelial Neoplasia